Intelligent Ultrasnd - GE Healthcare launches new ultrasound AI software
30/09/2020 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20200930:nRSd5145Aa
RNS Number : 5145A Intelligent Ultrasound Group PLC 30 September 2020
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company")
GE Healthcare launches new ultrasound AI software
GE Healthcare launches new Voluson SWIFT ultrasound system with industry first
auto recognition tools that incorporate the AI technology of Intelligent
Ultrasound
Intelligent Ultrasound (AIM: MED), the artificial intelligence (AI) based
ultrasound software and simulation company, today announced that GE Healthcare
has launched its new AI-enhanced Women's Health ultrasound system, Voluson
SWIFT*. The Voluson SWIFT features SonoLyst, the world's first fully
integrated AI tool that recognizes the 20 views recommended by the
International Society of Ultrasound in Obstetrics and Gynaecology
mid-trimester practice guidelines for fetal imaging and incorporates
Intelligent Ultrasound's ScanNav Assist AI technology.
SonoLyst features two applications that leverage Intelligent Ultrasound's
technology, SonoLystIR and SonoLystX. SonoLystIR performs automated detection
of the key scanning views and automated selection of the relevant Voluson
SonoBiometry measurement tools; and SonoLystX, a virtual on-board ultrasound
expert, uses AI to compare the acquired image to standardised criteria, to
ensure that it meets clinical standards. SonoLystX can help enhance accuracy
and quality and is ideal for teaching, training and quality assurance to
ensure the highest quality image standards and consistency.
SonoLyst is the first AI software to be launched under the Group's long-term
licence and co-development agreement with GE Healthcare that enables the
integration of Intelligent Ultrasound's real-time AI image analysis software
into GE Healthcare's Voluson women's health ultrasound portfolio. The first
royalty per unit revenues for Intelligent Ultrasound are expected at the start
2021.
*510(k) currently pending at FDA. Not available for sale in the United States.
Roland Rott, General Manager of Women's Health Ultrasound at GE Healthcare,
said:
"Voluson SWIFT has redefined one of the most essential tools obstetrics and
gynaecology clinicians rely on, delivering a contemporary design, intuitive
user interface, and intelligent workflow supported by AI. In today's
environment where cleanliness and time saving opportunities are critical for
clinicians, we're proud to offer a solution that makes our customers' work
easier and gives them time back with their patients."
Prof Aris Papageorghiou, Professor of Fetal Medicine, St George's Healthcare
NHS Trust, London said:
"I have worked in the field of AI in ultrasound for over ten years, yet I am
still amazed at the level of accuracy that has been achieved. You can really
see how Intelligent Ultrasound's AI technology, incorporated in the SonoLyst
software, will improve efficiency, make the learning of ultrasound easier and
reduce omissions and errors. It's a big advance for ultrasound imaging in
women's health."
Stuart Gall, CEO of Intelligent Ultrasound, said:
"It has been a pleasure to work with GE over the last year to bring this new
AI technology to market. The new Voluson SWIFT ultrasound system uses radical
innovations such as SonoLyst to bring new levels of efficiency to obstetric
ultrasound scanning. We are excited about our continuing collaboration to
bring the latest AI solutions to the market and wish GE Healthcare every
success with what we think is the future of ultrasound scanning in women's
healthcare."
For further information, please contact:
Intelligent Ultrasound Group plc www. intelligentultrasound.com
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cenkos Securities - Nominated Advisor and Broker Tel: +44 (0)20 7397 8900
Giles Balleny / Cameron MacRitchie (Corporate Finance)
Michael Johnson / Julian Morse (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com
Anna Dunphy / Paul McManus Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: MED) develops artificial
intelligence-based clinical image analysis software tools for the diagnostic
medical ultrasound market and hi-fidelity virtual reality simulators for the
ultrasound training market.
www.intelligentultrasound.com
(https://urldefense.proofpoint.com/v2/url?u=http-3A__www.intelligentultrasound.com&d=DwMF-g&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=fSst1AtlXyuqcs3cHJXcCRilbI1Qm1WfjNYkVgQfiLE&m=LLrsxIj7Hjtv7ET1faypmQFmcw6FK9mikL-lB2_KeBc&s=_unbOOQ-0BiN8XOLaMEHZ6rWI-BXk1tXuJOL3lhnf1E&e=)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCEAANNAEDEEAA